Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer

Abstract

Objective To investigate the impacts of cinobufotalin combined with docetaxel+cisplatin chemotherapy on the disease control and the level of vascular endothelial growth factor (VEGF) in serum of patients with non-small cell lung cancer. Methods Totally 70 patients with non-small cell lung cancer admitted to Zhejiang Veteran Hospital from March 2019 to March 2022 were included. They were randomly divided into combination group (cinobufotalin combined with docetaxel+cisplatin,n=35) and control group (docetaxel+cisplatin chemotherapy alone,n=35).The disease control rates of two groups, serum VEGF level, carcinoembryonic antigen (CEA), cytokeratin 19 (CK19) and carbohydrate antigen 125 (CA125) were measured using ELISA; life quality of patients was evaluated with the KPS score; The adverse events between two groups were compared. Results The disease control rate in the combination group (33/35, 94.29%) was higher than that that of control group (25/35, 71.43%,) (P＜0.05). After treatment, the level of VEGF in both groups of patients decreased, and the KPS score increased (P＜0.05) especially in the combination group (P＜0.05). After treatment, the level of serum CEA, CA125, and CK19 of control group and combination group were obviously lower than those before treatment(P＜0.05), while those in the combination group were even lower (P＜0.05). The incidence of adverse events in the combination group (5/35, 14.29%) was lower than that in the control group (13/35, 37.14%) (P＜0.05). Conclusions Cinobufotalin combined with docetaxel+cisplatin chemotherapy as a potential new chemotherapy significantly reduces the level of VEGF and tumor biomarkers in serum factor, improves the life quality of patients.The combined therapy is proved tobe safe.

Keywords

• cinobufotalin|dp chemotherapy|non-small cell lung cancer|vascular endothelial growth factor|disease control rate